XNPT – XenoPort, Inc is a biopharmaceutical company, focused on development and commercialization of drugs for the treatment of neurological and other disorders.
XNPT – Xenoport, Inc
|Fundamentals||Previously closed at||4.40|
|Analysts opinion||An Atlanta based private company, Arbor Pharmaceuticals has agreed to acquire XenoPort. Under the terms of agreement, XenoPort stockholders will receive $7.03 per share in cash. Johnson & Weaver, a nationally recognized attorney at law, has launched an investigation on whether the proposed deal price is adequate. Analyst confidence meter, a proprietary algorithm of Stockal gives a 70% buy based on analyst ratings.|
|Sentiments||XNPT rose 58% during pre-market today. The sentiment index is 50% positive according to Stockal proprietary algorithm.|
|Social Media Pulse||The stock has 100% higher social media chatter than usual.|